Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050108 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL15050110 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL6204443 | 0.83 | PPARG (0.46) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL15051251 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL15051252 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL15051250 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL16955932 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL11603896 | 0.82 | CES2 (0.55) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL4269110 | 0.81 | LMNA (0.57) | SLC6A2SLC6A4CES2CES1AOC3 | |
| SCHEMBL13661100 | 0.81 | LMNA (0.57) | SLC6A2SLC6A4CES2CES1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| EP-2797881-B1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-11-14 | — | — | EP | disclosed |
| US-9504668-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-01-28 | — | — | US | disclosed |
| EP-2968211-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-01-20 | — | — | EP | disclosed |
| US-9029589-B2 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-05-12 | — | — | US | disclosed |
| EP-2797881-A1 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | Bio-Pharm Solutions Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014142519-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013100566-A1 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MYLK, PDE3A, TNNC1 | SLC6A2 2071/4885SLC6A4 2148/4885CES2 505/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | SLC6A2 1757/4885SLC6A4 2975/4885CES2 1914/4885 |
| US-20160023999-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | SCN1A, GABARAPL1, NAA10 | SLC6A2 2696/4885SLC6A4 2646/4885CES2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.